0000000000175433
AUTHOR
A Giuliani
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…
Searching for New Physics in two-neutrino double beta decay with CUPID
Abstract In the past few years, attention has been drawn to the fact that a precision analysis of two-neutrino double beta decay (2υββ) allows the study of interesting physics cases like the emission of Majoron bosons and possible Lorentz symmetry violation. These processes modify the summed-energy distribution of the two electrons emitted in 2υββ. CUPID is a next-generation experiment aiming to exploit 100Mo-enriched scintillating Li2MoO4 crystals, operating as cryogenic calorimeters. Given the relatively fast half-life of 100Mo 2υββ and the large exposure that can be reached by CUPID, we expect to measure with very high precision the 100Mo 2υββ spectrum shape, reaching great sensitivities…